Menu Search
Equities

argenx SE

ARGX:NSQ

argenx SE

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)596.00
  • Today's Change4.56 / 0.77%
  • Shares traded180.95k
  • 1 Year change+20.18%
  • Beta0.5802
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy10
Outperform10
Hold4
Sell0
Strong Sell0

Share price forecast in USD

The 23 analysts offering 12 month price targets for argenx SE - ADR have a median target of 650.00, with a high estimate of 707.00 and a low estimate of 416.00. The median estimate represents a 9.06% increase from the last price of 596.00.
High18.6%707.00
Med9.1%650.00
Low-30.2%416.00

Earnings history & estimates in USD

On Oct 31, 2024, argenx SE - ADR reported 3rd quarter 2024 earnings of 1.39 per share. This result exceeded the 0.03 consensus of the 15 analysts covering the company and outperformed last year's 3rd quarter results by 2.64.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate+70.86%
argenx SE - ADR reported annual 2023 losses of -5.16 per share on Feb 29, 2024.
Average growth rate-40.32%
More ▼

Revenue history & estimates in USD

argenx SE - ADR had 3rd quarter 2024 revenues of 588.88m. This bettered the 538.52m consensus of the 21 analysts covering the company. This was 156.30% above the prior year's 3rd quarter results.
Average growth rate+15.16%
argenx SE - ADR had revenues for the full year 2023 of 1.27bn. This was 184.91% above the prior year's results.
Average growth rate+211.28%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.